Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    12-November-2000      
Issue 213 Next Update - 14:00 UTC 08:00 EST    13-November-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya FDA Approves 72-Hour Infusion Of Naporin

Naropin Is Currently The Only Long Acting Anesthetic With A 72-Hour Infusion Indication

AstraZeneca Pharmaceuticals announced this week that it has received approval from the US Food and Drug Administration for 72-hour infusion of Naropin (ropivacaine HCL), a long-acting anesthetic indicated for the production of local or regional anesthesia for surgery, post-operative pain management and for obstetrical procedures.

The company received approval for two changes in Naropin labeling: the first allows for dose increase from 5.0 mg/mL to 7.5 mg/mL for Major Nerve Blocks; the second grants approval for an increase in the duration of Naropin infusion from 24 hours to 72 hours for post-operative pain management.

"The 72-hour infusion indication allows pain management to extend well into the post-operative area with tremendous benefits to patients," said Roy Allan Greengrass, M.D., Associate Professor for the Department of Anesthesiology at Duke University. "It further reduces the need for pain management with opioids and can ultimately result in enhanced patient satisfaction."

Naropin is the only long acting anesthetic with a 72-hour infusion indication. In clinical trials the most commonly reported adverse events were hypotension, nausea, vomiting, bradycardia, fever, paresthesia and back pain.

Pain management is one of AstraZeneca's six therapeutic areas of focus. Other products developed and manufactured by AstraZeneca include Diprivan (propofol) Injectable Emulsion, EMLA (Lidocaine 2.5% and Prilocaine 2.5%), EMLA Anesthetic Disc (Lidocaine 2.5% and Prilocaine 2.5%) Topical Adhesive System and Xylocaine (Lidocaine HCl Injection, USP).

Prescribing information for Naporin is available in today's issue.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.